Attentiveness and mental health in adolescents with moderate-to-severe atopic dermatitis without ADHD

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
1 Online-Ressource.
Sprache
Englisch

Erschienen in
Attentiveness and mental health in adolescents with moderate-to-severe atopic dermatitis without ADHD ; volume:316 ; number:8 ; day:30 ; month:7 ; year:2024 ; pages:1-9 ; date:10.2024
Archives of dermatological research ; 316, Heft 8 (30.7.2024), 1-9, 10.2024

Urheber
Paller, Amy S.
Gonzalez, Mercedes E.
Barnum, Sarah
Jaeger, Judith
Shao, Liyang
Ozturk, Zafer E.
Korotzer, Andrew
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s00403-024-03210-x
URN
urn:nbn:de:101:1-2410230853466.462375827055
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:33 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Paller, Amy S.
  • Gonzalez, Mercedes E.
  • Barnum, Sarah
  • Jaeger, Judith
  • Shao, Liyang
  • Ozturk, Zafer E.
  • Korotzer, Andrew
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis

Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis

Effect of abrocitinib on skin biomarkers in patients with moderate‐to‐severe atopic dermatitis

Effect of abrocitinib on skin biomarkers in patients with moderate‐to‐severe atopic dermatitis

Lebrikizumab provides rapid response in EASI components and itch in moderate-to-severe atopic dermatitis

Lebrikizumab provides rapid response in EASI components and itch in moderate-to-severe atopic dermatitis

Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults

Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults

Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis

Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis

Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year

Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year

Economic Burden of Itch-Related Sleep Loss in Moderate-to-Severe Atopic Dermatitis in the United Kingdom

Economic Burden of Itch-Related Sleep Loss in Moderate-to-Severe Atopic Dermatitis in the United Kingdom

Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic Dermatitis

Eblasakimab, an Anti-IL‑13Rα1 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate‑to‑Severe Atopic Dermatitis

Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis

Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis

Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis

Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis

Atopic dermatitis

Atopic dermatitis

Verbundene Objekte